Searching for New Cancer Drugs by Studying DNA Topoisomerase I Inhibitors
Author Information
Author(s): Malgorzata N. Drwal, Keli Agama, Laureance P. G. Wakelin, Yves Pommier, Renate Griffith
Primary Institution: University of New South Wales, Sydney, Australia
Hypothesis
Can novel DNA topoisomerase I inhibitors be identified using structure- and ligand-based molecular modeling methods?
Conclusion
The study successfully identified several structurally novel topoisomerase I inhibitors that warrant further investigation as potential anticancer agents.
Supporting Evidence
- Seven compounds were tested for their Top1 inhibitory activity, with five showing mild to moderate inhibition.
- The approach successfully identified structurally novel Top1 inhibitors.
- Pharmacophore models were developed based on known Top1 inhibitors.
- Virtual screening of a large compound database led to the identification of diverse potential inhibitors.
Takeaway
The researchers looked for new cancer-fighting drugs by studying how certain compounds can stop a key enzyme in cancer cells from working.
Methodology
The study used structure- and ligand-based molecular modeling methods to identify potential topoisomerase I inhibitors from a large compound database.
Potential Biases
The study may be limited by the structural diversity of the training set used for pharmacophore modeling.
Limitations
The tested compounds displayed only low in vitro antitumor activity and the availability of compounds limited the testing.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website